SA pharmaceutical manufacturer Adcock Ingram has joined an international coalition of generic drugmakers pledging to work together to accelerate access to Covid-19 treatments for low and middle-income countries via the non-profit Medicines Patent Pool (MPP). 

The MPP was launched 10 years ago by the global health initiative Unitaid, funded by a levy on airline tickets. It has previously struck deals with several pharmaceutical companies to share their patents on treatments for HIV, tuberculosis, and hepatitis C with generic manufacturers in low and middle-income countries, including Adcock Ingram, which signed an agreement to make the HIV treatment dolutegravir...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now